0001601364-15-000001.txt : 20150126 0001601364-15-000001.hdr.sgml : 20150126 20150126165959 ACCESSION NUMBER: 0001601364-15-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150122 FILED AS OF DATE: 20150126 DATE AS OF CHANGE: 20150126 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Versartis, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 244106690 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4200 BOHANNON DRIVE STREET 2: SUITE 250 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 6509638580 MAIL ADDRESS: STREET 1: 4200 BOHANNON DRIVE STREET 2: SUITE 250 CITY: MENLO PARK STATE: CA ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Advent Life Sciences Fund I LP CENTRAL INDEX KEY: 0001601363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 15549185 BUSINESS ADDRESS: STREET 1: 158 NORTH GOWER STREET CITY: LONDON STATE: X0 ZIP: NW1 2ND BUSINESS PHONE: 44 (0) 207 932 2120 MAIL ADDRESS: STREET 1: 158 NORTH GOWER STREET CITY: LONDON STATE: X0 ZIP: NW1 2ND REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Advent Life Sciences LLP CENTRAL INDEX KEY: 0001601364 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 15549186 BUSINESS ADDRESS: STREET 1: 158 NORTH GOWER STREET CITY: LONDON STATE: X0 ZIP: NW1 2ND BUSINESS PHONE: 44 (0) 207 932 2120 MAIL ADDRESS: STREET 1: 158 NORTH GOWER STREET CITY: LONDON STATE: X0 ZIP: NW1 2ND 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2015-01-22 0 0001513818 Versartis, Inc. VSAR 0001601364 Advent Life Sciences LLP 158 NORTH GOWER STREET LONDON X0 NW1 2ND UNITED KINGDOM 0 0 0 1 Affiliate of Director 0001601363 Advent Life Sciences Fund I LP 158 NORTH GOWER STREET LONDON X0 NW1 2ND UNITED KINGDOM 0 0 0 1 Affiliate of Director Common Stock 2015-01-22 4 P 0 55000 17.25 A 2271558 I See FN Option (Right to Buy) 21 2014-03-19 Common Stock 35000 35000 I See FN Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund. Advent disclaims beneficial ownership of the shares held by Advent Fund except to the extent of its indirect pecuniary interest therein. Shahzad Malik, an affiliate of the Reporting Persons, is a member of the Issuer's board of directors, and disclaims beneficial ownership of the shares held by Advent or the Advent Fund except to the extent of his indirect pecuniary interest therein. One-fourth of the total number of shares subject to the option shall vest and become exercisable one year from 3/21/2014 (the "Vesting Commencement Date") and 1/36th of the remaining number of shares subject to the option shall vest and become exercisable on each monthly anniversary of the Vesting Commencement Date thereafter. Securities are held by Shahzad Malik, an affiliate of the Reporting Persons. The Reporting Persons disclaim beneficial ownership of the securities held by Shahzad Malik. The Reporting Persons are no longer greater than 10% holders. Shahzad Malik, an affiliate of the Reporting Persons, is a member of the Issuer's board of directors. /s/ Shahzad Malik, General Partner, Advent Life Sciences LLP 2015-01-26 /s/ Shahzad Malik, General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP 2015-01-26